The HDAC1 Knockout NCI-H1703 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population generated from the NCI-H1703 human lung squamous cell carcinoma cell line. This heterogeneous pool harbors targeted disruptions in the HDAC1 gene, producing a functional loss-of-function model that avoids clonal selection bias. The polyclonal format ensures that the resulting cell population retains a range of edited alleles, enabling studies of HDAC1 biology in a context that more closely mirrors natural genetic heterogeneity.
Parental NCI-H1703 cells were originally derived from the lung squamous cell carcinoma of a 55-year-old male smoker and exhibit adherent epithelial morphology. This cell line is a widely utilized model for squamous cell lung cancer, retaining genomic alterations characteristic of the disease. By using this background for HDAC1 knockout, investigators can directly assess the functional consequences of HDAC1 disruption in a tumor-relevant cellular environment.
HDAC1 encodes a class I histone deacetylase that deacetylates lysine residues on histones H3 and H4, promoting chromatin condensation and transcriptional repression. It functions within Sin3, NuRD, and CoREST corepressor complexes, interacting with SIN3A, MTA2, MBD3, RCOR1, and KDM1A. Upstream regulators include E2F1, TP53, STAT3, SP1, and CSNK2A1. Downstream, HDAC1 represses CDKN1A, BAX, and CDH1, while modulating MYC and CCND1. Through these interactions, HDAC1 integrates signals from RB1/E2F, p53, TGF-??/SMAD, and WNT/CTNNB1 pathways to control cell cycle, apoptosis, and differentiation. The HDAC1?CSIN3A?CRB1 axis cooperates in silencing E2F targets, and interplay with TP53 and BCL2 family members influences apoptosis.
In lung squamous cell carcinoma, HDAC1 is frequently overexpressed, contributing to the epigenetic silencing of tumor suppressor genes and promoting unchecked proliferation. The NCI-H1703 polyclonal HDAC1 knockout cells offer a physiologically relevant platform to dissect HDAC1??s role in maintaining the malignant phenotype. Ablation of HDAC1 in this context permits examination of de-repressed target genes, global changes in histone acetylation, and altered sensitivity to chemotherapeutic agents or HDAC inhibitors. This model is especially useful for investigating mechanisms of resistance to epigenetic therapies and for validating HDAC1 as a therapeutic target in squamous cell carcinomas.
Typical research applications include functional studies of HDAC1 in lung squamous cell carcinoma, epigenetic regulation of gene expression, and screening of HDAC inhibitors such as vorinostat and trichostatin A. The polyclonal knockout cells are well suited for western blotting and RT-qPCR to confirm HDAC1 loss, cell proliferation (MTT or BrdU) and apoptosis (Annexin V/PI) assays, and chromatin immunoprecipitation (ChIP) to monitor histone H3 and H4 acetylation at target loci. Additional analyses such as HDAC activity assays, migration/invasion tests, and drug sensitivity profiling provide comprehensive insights into HDAC1-driven biology. For further information or technical assistance, please contact Ascent Research.
